Oncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens.
10.3393/jksc.2012.28.5.259
- Author:
Yoo Sung LEE
1
;
Hee Cheol KIM
;
Kyung Ook JUNG
;
Yong Beom CHO
;
Seong Hyeon YUN
;
Woo Yong LEE
;
Ho Kyung CHUN
Author Information
1. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. hckim@skku.edu
- Publication Type:Original Article
- Keywords:
Stage IIIA;
Colon neoplasm;
Chemotherapeutic agent;
Prognosis
- MeSH:
Chemotherapy, Adjuvant;
Colon;
Colonic Neoplasms;
Disease-Free Survival;
Female;
Follow-Up Studies;
Humans;
Male;
Prognosis;
Prospective Studies;
Rectal Neoplasms;
Retrospective Studies
- From:Journal of the Korean Society of Coloproctology
2012;28(5):259-264
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Adjuvant chemotherapy is currently recommended for Stage IIIA colon cancers. This study aimed to elucidate the oncologic outcomes of Stage IIIA colon cancer according to the chemotherapeutic regimen based on a retrospective review. METHODS: From 1995 to 2008, Stage IIIA colon cancer patients were identified from a prospectively maintained database at a single institution. Exclusion criteria were as follows: rectal cancer, another malignancy other than colon cancer, no adjuvant chemotherapy and unknown chemotherapeutic regimen. One hundred thirty-one patients were enrolled in the study, and the clinicopathologic and the oncologic characteristics were analyzed. The number of males was 72, and the number of females was 59; the mean age was 59.5 years (range, 25 to 76 years), and the median follow-up period was 33 months (range, 2 to 127 months). RESULTS: Of the 131 patients, fluorouracil/leucovorin (FL)/capecitabine chemotherapy was performed in 109 patients, and FOLFOX chemotherapy was performed in 22 patients. When the patients who received FL/capecitabine chemotherapy and the patients who received FOLFOX chemotherapy were compared, there was no significant difference in the clinicopathologic factors between the two groups. The 5-year overall survival and the 5-year disease-free survival were 97.2% and 94.5% in the FL/capecitabine patient group and 95.5% and 90.9% in the FOLFOX patient group, respectively, and no statistically significant differences were noted between the two groups. CONCLUSION: Stage IIIA colon cancer showed good oncologic outcomes, and the chemotherapeutic regimen did not seem to affect the oncologic outcome.
